Baxter International (BAX Quick QuoteBAX - Free Report) entered 2026 focused on executing a broad turnaround strategy aimed at restoring growth, improving cash flow and strengthening operational discipline. While innovation initiatives, solid demand in select businesses and improving balance-sheet trends support its long-term outlook, regulatory challenges, margin pressure and continued weakness in certain core segments remain significant near-term headwinds.

Shares of this Zacks Rank #3 (Hold) company have gained 8.9% so far this year against the industry's 23.2% decline. The S&P 500 Index has jumped 8.6% during the same time frame.

BAX, with a market capitalization of $10.1 billion, is a global medical technology company providing items, such as infusion pumps and intravenous solutions. The company has an earnings yield of 9.2% compared with the industry's 3.3%. It anticipates earnings to improve 3.2% over the next five years.

Image Source: Zacks Investment Research

Positive Factors Driving Prospects

Turnaround Strategy Leading to Operational Progress: Baxter’s new management team is focused on stabilizing the business through its multi-pronged turnaround strategy centered on operational discipline, balance sheet repair and continuous improvement. The newly implemented Baxter Growth and Performance System (“GPS”) has already driven more than several improvement initiatives across the organization, helping improve execution, service reliability and working capital efficiency.

While the turnaround remains in its early stages, the framework introduces greater accountability by decentralizing P&L ownership and streamlining decision-making. This operational transformation should gradually restore consistency in revenue growth, improve margins and rebuild investor confidence.

Advanced Surgery and Healthcare Technology Remain Resilient: Despite broader operational challenges, Baxter continues to benefit from strong demand in several higher-growth businesses. Advanced Surgery revenues grew 10% in the first quarter of 2026, supported by steady procedure volumes and continued demand for hemostats and sealants across global markets.

In Healthcare Systems & Technologies, management highlighted strong momentum in Patient Support Systems and a healthy U.S. capital equipment order book, suggesting that hospital capital spending remains resilient despite broader macroeconomic uncertainty. However, continued execution will be critical to sustaining this momentum and offsetting ongoing challenges in other areas of the business.

These businesses represent strategically attractive segments with better growth profiles than legacy infusion-related products. This provides Baxter with an important growth cushion while management works through operational and regulatory challenges elsewhere in the portfolio.

Innovation Pipeline and AI Integration to Support Growth: Baxter is increasingly positioning innovation as a future growth catalyst, with management highlighting multiple recent product launches, including Dynamo smart hospital stretcher, Connex 360 connected-care platform, IV Verified automated medication labeling system and XR spine surgical table.

BAX is also aggressively integrating AI into both product development and internal operational workflows. Management emphasized that AI is already being deployed across connected-care infrastructure, manufacturing systems and quality workflows to improve clinical decision-making and operational efficiency. 

Baxter’s growing emphasis on incremental innovation and AI-driven healthcare solutions could gradually improve its competitive positioning and likely lead to stronger organic growth drivers.

Key Challenges

Core Business Performance Remains Weak: Baxter’s underlying operating performance remains weak. First-quarter revenues increased 3%, reportedly, but organic sales declined 1%, while adjusted EPS fell sharply 35% year over year to 36 cents. Multiple core businesses remain under pressure, including Medical Products & Therapy, Healthcare Systems Technology and Pharmaceuticals.

The company’s guidance for approximately flat organic sales growth for full-year 2026 indicates management does not expect meaningful near-term acceleration. While executives are emphasizing second-half improvement, current performance suggests Baxter is still operating well below its earnings potential.

Novum Infusion Pump Regulatory Problems Continues: The largest company-specific overhang remains Baxter’s ongoing Novum LVP infusion pump regulatory issue, which continues to prevent shipment and installation activity.

Management confirmed that the shipment hold is fully reflected in its full-year guidance. However, the company acknowledged that customer returns or product exchanges could still occur, creating an additional layer of uncertainty around future financial performance.

Although customer returns were immaterial during the first quarter, management repeatedly emphasized it remains prudent to maintain this risk assumption throughout 2026. The infusion pump portfolio accounts for less than 2% of total revenues, but the broader concern extends beyond lost pump sales into associated high-margin consumables, customer retention and reputational damage within hospital infusion systems.

Margin Compression Remains Severe: Baxter’s profitability deteriorated significantly during the quarter as multiple external and operational pressures simultaneously hit margins. Adjusted gross margin declined 500 basis points to 36.8%, while operating margin fell 390 basis points to 11%.

Management cited approximately $50 million of cost timing headwinds, higher tariff-related costs, elevated manufacturing expenses and lower production absorption. The company continues to estimate a full-year tariff-related headwind of approximately $80 million. In addition, it remains exposed to inflationary pressures from higher oil prices, freight expenses, semiconductor supply constraints and rising raw-material costs, all of which could weigh on profitability if they persist.

Although management expects roughly 500 basis points of second-half margin recovery, much of the pressure stems from external factors outside Baxter’s control. Sustained cost inflation could materially delay the company’s earnings recovery timeline.

Baxter International Inc. Price

Baxter International Inc. price | Baxter International Inc. Quote

Estimate Trend

The Zacks Consensus Estimate for 2026 revenues is pegged at $11.36 billion, indicating a 1% improvement from the previous year’s level.

The consensus mark for adjusted earnings per share (EPS) is pinned at $1.92, indicating a 15.4% decrease from the year-ago reported number. The consensus estimate for adjusted EPS has improved 1 cent in the past 60 days.

Stocks to Consider

Some better-ranked stocks from the same medical industry are Align Technology (ALGN Quick QuoteALGN - Free Report) , West Pharmaceutical Services (WST Quick QuoteWST - Free Report) and Cardinal Health (CAH Quick QuoteCAH - Free Report) .

Align Technology, carrying a Zacks Rank #1 (Strong Buy) at present, has an estimated long-term growth rate of 10.3%. ALGN’s earnings surpassed estimates in three of the trailing four quarters and missed once, with the average surprise being 7.80%. You can see the complete list of today’s Zacks #1 Rank stocks here.

ALGN’s shares have gained 9.2% against the industry’s 4.2% decline so far this year.

West Pharmaceutical, currently carrying a Zacks Rank of 1, has an estimated long-term growth rate of 13.9%. WST’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 19.37%.

West Pharmaceutical’s shares have gained 20.2% against the industry’s 4.2% decline year to date.

Cardinal Health, currently carrying a Zacks Rank #2 (Buy), has an estimated long-term growth rate of 17%. CAH’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 10.27%.

CAH’s shares have gained 5.2% against the industry’s 4.2% decline so far this year.